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Abstract
The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is the etiological agent for the infectious disease, SARS,
which first emerged 10 years ago. SARS-CoV is a zoonotic virus that has crossed the species barriers to infect humans. Bats,
which harbour a diverse pool of SARS-like CoVs (SL-CoVs), are believed to be the natural reservoir. The SARS-CoV surface
Spike (S) protein is a major antigenic determinant in eliciting neutralizing antibody production during SARS-CoV infection. In
our previous work, we showed that a panel of murine monoclonal antibodies (mAbs) that target the S2 subunit of the S
protein are capable of neutralizing SARS-CoV infection in vitro (Lip KM et al, J Virol. 2006 Jan; 80(2): 941–50). In this study, we
report our findings on the characterization of one of these mAbs, known as 1A9, which binds to the S protein at a novel
epitope within the S2 subunit at amino acids 1111–1130. MAb 1A9 is a broadly neutralizing mAb that prevents viral entry
mediated by the S proteins of human and civet SARS-CoVs as well as bat SL-CoVs. By generating mutant SARS-CoV that
escapes the neutralization by mAb 1A9, the residue D1128 in S was found to be crucial for its interaction with mAb 1A9. S
protein containing the substitution of D1128 with alanine (D1128A) exhibited a significant decrease in binding capability to
mAb 1A9 compared to wild-type S protein. By using a pseudotyped viral entry assay, it was shown that the D1128A
substitution in the escape virus allows it to overcome the viral entry blockage by mAb 1A9. In addition, the D1128A
mutation was found to exert no effects on the S protein cell surface expression and incorporation into virion particles,
suggesting that the escape virus retains the same viral entry property as the wild-type virus.
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Introduction
The Severe Acute Respiratory Syndrome (SARS) first emerged
as an infectious disease ten years ago, manifesting itself as a severe
form of pneumonia. Its etiological agent was identified as a then
novel coronavirus known as the SARS coronavirus (SARS-CoV)
[1,2]. Within a short span of time from December 2002 to July
2003, the newly emerged virus spread quickly to infect more than
8000 people across 25 countries with an overall fatality rate of
approximately 10% [3]. SARS-CoV is a zoonotic virus that has
crossed the species barrier to infect humans. Small animals such as
palm civets (Paguma larvata) and raccoon dogs (Nyctereutes procyno-
noides) sold in live-animal wet markets in Guangdong Province of
Southern China are believed to be the zoonotic source of the virus
transmitted to humans [4]. In 2005, the complete sequences of
SARS-like coronaviruses (SL-CoVs) of genetic homology of 87–
92% to SARS-CoV were identified from horseshoe bats of the
genus Rhinolophus in China [5,6]. However, these SL-CoVs display
significant differences in sequences at the receptor-binding domain
(RBD) compared to SARS-CoV and are unable to use the SARS-
CoV receptor, the human angiotensin-converting enzyme 2
(ACE2), for cellular entry [7], rendering them unlikely to be the
immediate progenitor of SARS-CoV. More recently, a bat SL-
CoV capable of using the human ACE2 receptor for cellular entry
was characterized and isolated from Chinese horseshoe bats,
providing strong evidence that bats are the natural reservoirs of
SARS-CoV [8].
The SARS-CoV is classified as a virus from the genus
betacoronavirus (lineage B), family Coronaviridae and order
Nidovirales. It is an enveloped, positive-sense, single-stranded
RNA virus of genome size of approximately 29.7 kb, encoding
for 16 non-structural proteins, 8 accessory proteins and 4
structural proteins (namely the spike [S], envelope [E], membrane
[M] and nucleocapsid [N] proteins) [9,10,11]. Every surface spike
of the SARS-CoV is composed of a trimer of S protein of 1255
amino acids in length. The S protein is a type 1 glycoprotein and a
class 1 fusion protein responsible for viral attachment and entry
into host cells, and is therefore the principal determinant of host
range [12]. It consists of 2 functional subunits: the N-terminal S1
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subunit (amino acids 15–679) and the C-terminal S2 subunit
(amino acids 680–1255). The S1 subunit contains the RBD
[13,14] that recognizes the SARS-CoV receptor, ACE2 [15],
allowing the attachment of the virus to its host cell. The S2 subunit
contains the putative fusion peptide and two heptad repeats, HR1
and HR2, important in SARS-CoV fusion with target host cells
[16,17]. Upon the association of the RBD with the ACE2
receptor, a conformational change of S2 is triggered, resulting in
the insertion of the fusion peptide into the target cell membrane
[18], followed by the interaction of the HR1 and HR2 domains in
an anti-parallel manner to form a stable six-helical bundle fusion
core [17,19]. This allows the viral membrane and target cell
membrane to come into close proximity, facilitating membrane
fusion and viral entry [20,21].
Besides its roles in viral entry, the S protein is also a major
antigenic determinant in eliciting humoral immune responses in
infected humans [22] and is therefore an important target in the
development of vaccines and therapeutic intervention against
SARS [23,24]. Numerous human and murine monoclonal
antibodies (mAbs) binding to the S1 or S2 regions of the S protein
have been identified and were shown to confer neutralizing
activities in vitro and protection in vivo against SARS-CoV infection
[25,26,27,28]. The S1 subunit of the S protein, especially the
RBD, is highly variable among coronaviruses, resulting in a wide
range of tissue tropism, while the S2 subunit is a well-conserved
domain, indicating the highly conserved nature of the fusion
process [29]. As a result, anti-S2 mAbs have broadly neutralizing
characteristics against a wider range of SARS-CoV variants,
including human and zoonotic SARS-CoV strains, through the
recognition of highly-conserved epitopes [28,30]. In our previous
study, it has been shown that a panel of murine mAbs targeting the
HR2 domain and the region upstream of HR2 of the S protein are
capable of neutralizing SARS-CoV infection in vitro [31]. In this
study, the cross-neutralization ability of one of these mAbs, termed
as 1A9, was investigated by studying its ability to prevent viral
entry mediated by the S protein of SARS-CoV strain from civet as
well as SL-CoV strains from bats. MAb 1A9 binds to the loop
region between the HR1 and HR2 domains and this region is
highly conserved but has no known function (Figure 1). In
addition, escape mutants against mAb 1A9 were generated to
identify critical residues important for mAb 1A9 binding to S
protein. We found that mAb 1A9 has broad cross-neutralizing
activity and identified a single amino acid (aspartic acid) at position
1128 in S to be crucial for the interaction with mAb 1A9. By using
a pseudotyped viral entry assay, it was shown that the substitution
of this residue with alanine (D1128A) mediates escape from mAb
1A9 neutralization. In addition, the D1128A mutation exerts no
effects on the expression of S on the cell surface and its
incorporation into virion particles, suggesting that the escape
virus retains the same viral entry property as the wild-type virus.
Materials and Methods
Ascites production
Ascites were produced by injecting hybridoma cells into the
peritoneal cavities of pristine-primed BALB/c mice. The protocol
was approved by the Institutional Animal Care and Use
Committee (IACUC) of the Biological Resource Centre, A*Star,
Singapore (Protocol Number: 110694). All the procedures were
carried out in strict accordance with the recommendations of the
National Advisory Committee for Laboratory Animal Research
(NACLAR) guidelines in Singapore. All efforts were made to
minimize suffering and euthanasia was performed using carbon
dioxide.
Cells and virus
Vero E6 (American Type Culture Collection) and 293 FT cells
(Invitrogen) were grown in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% fetal bovine serum (Hyclone),
nonessential amino acids (Gibco) and penicillin (10,000 units/ml)-
streptomycin (10 mg/ml) solution (Sigma Aldrich). CHO cell line
stably expressing the human ACE2, known as CHO-ACE2, was
established previously [31], and cultured in the same medium. All
cell lines were maintained at 37uC with 5% CO2. The human
SARS-CoV strain HKU39849 was used in this study.
Purification of monoclonal antibodies
Antibodies were purified from the ascites by using affinity
chromatography. Briefly, a 1 ml HiTrap Protein G HP beads
column (GE Healthcare) was pre-washed using ,20 ml of 20 mM
sodium phosphate buffer, pH 7.0 at a constant flow-rate of 1 ml/
min using a peristaltic pump. 5 ml of ascites fluids were mixed
with equal volume of 40 mM sodium phosphate buffer and passed
through a 0.45 mm filter. The filtered ascites fluids were passed
through the column at the same flow-rate of 1 ml/min. Extensive
washing was performed using the 20 mM sodium phosphate
buffer. Elution buffer (0.1 M glycine-HCl, pH 2.7) was then
passed through the column at a flow-rate of 1 ml/min and the
flow-through was collected at 0.5 ml fractions in 1.5 ml micro-
tubes containing 20 ml of neutralization buffer (1 M Tris-HCl,
pH 9.0). The concentration of the purified monoclonal antibodies
in each tube was determined using the Coomassie Plus protein
assay reagent (Thermo Scientific).
Generation of escape mutants
The generation of escape mutants was performed in a biosafety
level 3 (BSL-3) laboratory. Using 100 TCID50 of SARS-CoV
(strain HKU39849) for infection of Vero E6 cells in the presence of
different concentrations of mAb 1A9, the concentration of mAb
1A9 that reduced the virus titers by about 4 logarithms (log) was
determined to be 0.25 mg/ml and used for the generation of virus
escape mutants. Serial dilutions of SARS-CoV ranging from 1021
to 1028 were incubated in the presence of 0.25 mg/ml of mAb
1A9 for 1 h at 37uC and 5% CO2. The virus-mAb mixtures were
then incubated with Vero E6 cells in a 96-well plate for 1 hour at
37uC and 5% CO2, after which the virus-mAb mixtures were
removed and the cells were washed twice with medium. The cells
were further incubated for 2 days in the presence of mAb 1A9 at
concentration 0.25 mg/ml. The supernatant from the wells
containing cells that exhibited cytopathic effect (CPE) at the
highest dilution of SARS-CoV was harvested. The percentage
CPE was determined by visual counting of floating cells and
attached cells. Wells with more than 80% floating cells are
considered to have CPE. This supernatant was again incubated in
the presence of 0.25 mg/ml of mAb 1A9 for 1 h at 37uC before
the virus-mAb mixture was used to infect Vero E6 cells in the
presence of mAb 1A9 at concentration 0.25 mg/ml. This was
performed 3 times. The final virus sample was added to Vero E6
cells in a 6-well plate and incubated for 1 hour at 37uC and 5%
CO2 before the wells were overlaid with agarose containing
0.25 mg/ml mAb 1A9 and incubated for 3–5 days at 37uC and
5% CO2. Five plaques were picked using a pasteur pipette, freeze-
thawed once and further amplified in Vero E6 cells. Neutralization
tests were then performed on all the virus clones to confirm that
they could escape neutralization by mAb 1A9.
Characterization of SARS Coronavirus Antibody Escape Virus
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TOPO cloning and sequencing
Viral RNA of the 5 escape virus clones was isolated using the
QIAamp viral RNA mini kit (Qiagen) and converted into cDNA
by standard reverse transcription (SuperScript II Reverse Tran-
scriptase, Invitrogen). The cDNA was then amplified by PCR
using specific primers targeting the S gene to generate a long
fragment (amino acids 1 to 1003) and a short fragment (amino
acids 969 to 1255). These gene fragments were cloned into
pCR2.1-TOPO vector (Invitrogen) and five colonies were
sequenced.
Figure 1. Binding site of mAb 1A9 within the SARS-CoV S protein. (A) Schematic diagram of the different motifs in the SARS-CoV S protein.
RBD, receptor binding domain; HR1, heptad repeats 1 domain; HR2, heptad repeats 2 domain. Black box represents the domain in S that is required
for the interaction with mAb 1A9. (B) The S region corresponding to the binding site of mAb 1A9 (boxed) to human SARS-CoV HKU39849 strain is
aligned with that of civet SARS-CoV SZ3 strain, bat SL-CoV Rp3 and Rf1 strains. Two residues upstream of this binding site are not conserved and they
have been underlined.
doi:10.1371/journal.pone.0102415.g001
Figure 2. Binding and neutralization of human, civet SARS-CoVs and bat SL-CoVs to mAb 1A9. (A) Schematic representation of chimeric
S protein of civet SARS-CoV SZ3, bat SL-CoVs Rp3 and Rf1. The civet SARS-CoV SZ3 chimeric S contains four mutations (R344K, S360F, K479N and
S485T) at its RBD that is different from the RBD of human SARS-CoV HKU39849. The bat SL-CoVs Rp3 and Rf1 chimeric S proteins had their entire RBD
(amino acids 322–496) replaced by the RBD of human SARS-CoV HKU39849 (amino acids 318–518). (B) 293 FT cells were transfected with no plasmid
(mock) or with plasmids expressing S of human SARS-CoV HKU39849, RBD-modified chimeric S of civet SARS-CoV SZ3, bat SL-CoV Rp3 and Rf1
respectively. Western Blot analysis was performed on the cell lysates using mAb 1A9 to determine if it can bind to different S proteins. MAb 7G12,
which binds to the S1 of the S protein, was used as a control antibody to detect protein expression. (C) S-pps containing S of human HKU39849, civet
SZ3, bat Rp3 or Rf1, were pre-incubated with different concentrations of mAb 1A9 at 100, 150 and 200 mg/ml for 1 hour before infecting CHO-ACE2
cells. Cells were harvested 48 hours post-infection and luciferase activities were measured. Viral entry, as indicated by the luciferase activity measured
in relative light units (RLU), was expressed as a percentage of the reading obtained in the absence of antibody, which was set at 100%. Data shown
represents that obtained from 3 independent experiments. Bars represent SD of the experiment carried out in triplicates.
doi:10.1371/journal.pone.0102415.g002
Characterization of SARS Coronavirus Antibody Escape Virus
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e102415
Construction of plasmids for expression in mammalian
cells
The S gene of the human SARS-CoV HKU39849 strain was
obtained from viral RNA after reverse transcription and PCR and
cloned into the pXJ39 expression vector using the BamHI and
XhoI restriction sites (pXJ39-S). Chimeric S genes of civet SARS-
CoV SZ3 strain, bat SL-CoV Rp3 and Rf1 strains were designed
by replacing their receptor-binding domain (RBD) with that of the
human SARS-CoV HKU39849 strain. For SZ3, the arginine (R)
residue at position 344 was substituted with lysine (K); serine (S)
residue at position 360 was substituted with phenylalanine (F);
lysine at position 479 was substituted with asparagines and serine
at position 487 was substituted with threonine (T). For Rp3 and
Rf1, the RBD domain of amino acids 322–496 was replaced with
the RBD domain (amino acids 318–510) of the human
HKU39849. They were then chemically synthesized (GenScript
USA Inc., Piscataway, NJ) and cloned into the same expression
vector by using the same restriction sites.
To generate plasmids for the expression of mutant S, specific
primers were designed for two-round PCR site-directed mutagen-
esis of wild-type S gene using the Expand High Fidelity PCR
System (Roche). The PCR products were then cloned into the
pXJ39 expression vector using BamHI and XhoI restriction sites to
form pXJ39-S-N1056K, pXJ39-S-D1128A, pXJ39-S-D1128A/
N1056K, pXJ39-S-D1128E and pXJ39-S-D1128N plasmids.
Western Blot analysis and immunoprecipitation (IP)
Expression plasmids expressing wild-type and mutant human
SARS-CoV S, chimeric civet SARS-CoV SZ3 S, bat SL-CoV Rp3
and Rf1 S genes were transiently transfected into 293 FT cells
using Lipofectamine 2000 reagent (Invitrogen) according to
manufacturer’s protocol. The cells were harvested at 24 hours
post-transfection by scrapping and cells were spun down by
Figure 3. Generation of escape SARS-CoV mutant virus in the
presence of mAb 1A9. Human SARS-CoV HKU39849 strain was
cultured in Vero E6 cells in the absence or presence of mAb 1A9
(0.25 mg/ml). Supernatant from the wells containing cells that
exhibited cytopathic effect (CPE) at the highest dilution of SARS-CoV
was harvested as passage 1. The virus was then passaged 3 times in the
presence of mAb 1A9 (0.25 mg/ml) and the virus supernatant harvested
at each passage was titrated on Vero E6 cells.
doi:10.1371/journal.pone.0102415.g003
Figure 4. Neutralization of wild-type and 1A9 escape SARS-CoV virus by mAb 1A9 and mAb 1G10. Wild-type human SARS-CoV
HKU39849 strain (A and C) and escape mutant SARS-CoV virus generated in the presence mAb 1A9 (B and D) were used at 1000 TCID50 to infect Vero
E6 cells in the presence of two mAbs, namely mAb 1A9 (A and B) and mAb 1G10 (C and D). MAb 1A9 was used at concentrations 0, 0.25, 0.5, 1.0 and
2.0 mg/ml while mAb 1G10 was used at concentrations 0, 0.125, 0.25, 0.5 and 1.0 mg/ml. Percentage cytopathic effects (% CPE) of the infected cells
was observed. MAb 1G10, a SARS-CoV-neutralizing, anti-S2 mAb that binds to S2 at residues 1151–1192, was used as the control mAb.
doi:10.1371/journal.pone.0102415.g004
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centrifugation and washed with cold PBS twice. Cell were then
resuspended in lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl,
0.5% NP40, 0.5% deoxycholic acid, 0.005% SDS and 1 mM
phenylmethylsulfonyl fluoride) and subjected to freeze-thaw five
times followed by spinning down at 13,000 rpm to remove cell
debris. Cell lysate protein concentrations were quantitated using
the commassie plus protein assay reagent (Thermo Scientific) for
use in Western blot analysis and immunoprecipitation (IP). In
Western blot analysis, proteins were separated on a 7.5%
polyacrylamide gel by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose
membranes. The membranes were blocked in 5% skimmed milk
in tris-buffered saline (TBS) with 0.05% Tween 20 (TBST) and
incubated with primary antibodies, mAbs 1A9 and 7G12 [31]
overnight at 4uC. The membranes were then washed in TBST
before incubation with goat anti-mouse horseradish peroxidase
(HRP)-conjugated antibody (Pierce) as the secondary antibody at
room temperature for 1 hour. The membranes were washed in
TBST again followed by the addition of enhanced chemilumines-
cence substrate (Pierce) for film development.
In IP, mAbs 1A9 and 7G12 were used to pull down wild-type
and mutant S proteins in the cell lysates for 1 hour at 4uC,
followed by the addition of protein A beads (Roche) and
incubation at 4uC overnight. The beads were then washed in
lysis buffer three times and subjected to Western blot analysis for
the detection of S proteins using the rabbit anti-SD1 antibody
(binds to amino acids 48–358 of the S1 subunit) [32] as primary
antibody and goat anti-rabbit HRP-conjugated antibody (Pierce)
as secondary antibody.
Expression and purification of S fragments in bacteria
A fragment of S(1030-1188 aa) was expressed as a GST
(glutathione-transferase) fusion protein using the pGEX6p1 vector
(GE healthcare). This fragment is located in the S2 subunit at
amino acids 1030-1188 and contains the mAb 1A9 binding site.
The wild-type and mutant (N1056K and D1128A) S fragments
were expressed in Escherichia coli BL21-DE3. Cultures were grown
in Terrific Broth and on reaching an optical density at 600 nm
(OD600 nm) of 0.8, cells were cooled to 16uC and induced with
isopropyl b-D-thiogalactopyranoside (IPTG) at a final concentra-
tion of 0.5 mM. After an incubation period of 24 hours, cells were
harvested. Bacterial pellets were resuspended in lysis buffer
containing 20% sarkosyl and subjected to sonication. The lysate
was cleared by centrifugation and incubated with gluthathione
(GSH) sepharose beads (GE Heathcare) overnight at 4uC. After
several washes, the GST-tagged S fragments were eluted from the
beads in 10 mM reduced gluthathione solution (Sigma Aldrich).
Purified S fragments were then subjected to SDS-PAGE on a 12%
gel and stained using coomassie blue to visualize the purity of
proteins.
Enzyme-linked immunosorbent assay (ELISA)
Purified wild-type and mutant (N1056K and D1128A) GST-
S(1030–1188 aa) proteins were coated onto 96-well ELISA plates
(Nunc) overnight at 4uC at 100 ng/well. The wells were blocked in
5% skimmed milk in phosphate-buffered saline (PBS) with 0.1%
Tween 20 (PBST) for 1 hour at room temperature, and primary
antibodies (mAb 1A9 and mouse anti-GST antibody [Santa Cruz])
were added as primary antibodies at 4-fold dilutions and incubated
at 37uC for 2–3 hours. The wells were then washed in PBST
followed by the addition of goat anti-mouse HRP-conjugated
antibody (Pierce) as secondary antibody and incubated at 37uC for
1 hour. Tetramethylbenzidine substrate (Pierce) was added and
reaction was stopped using 0.2 M sulphuric acid. Optical density
at 450 nm (OD450 nm) was obtained using an absorbance reader
(Tecan Infinite M200). Statistical difference in binding of mAb
1A9 to wild-type S and mutant S was analysed using unpaired t-
test. Significance was indicated by p-value of ,0.01.
Generation of pseudotyped particles expressing S on the
surface (S-pp)
The ability of SARS-CoV containing mutant S to infect cells
and the resulting effect in mAb neutralization in SARS-CoV entry
were studied using a pseudotyped virus system. Based on this
pseudotyped virus system, replication incompetent lentiviral
particles expressing S proteins on the surface and containing the
firefly luciferase reporter gene were used in replacement of live
SARS-CoVs. Viral entry into permissive cell lines will be reflected
in the luciferase activity of the infected cells. To generate S-
pseudotyped particle (S-pp), lentiviral vector pNL43-R-E-Luc and
plasmids expressing S genes were co-transfected in 293 FT cells
using Lipofectamine 2000 reagent (Invitrogen) according to
manufacturer’s protocol. 48 hours post-transfection, the viral
supernatant was collected and spun down in a centrifuge to
remove cell debris. P24 ELISA (QuickTiter Lentivirus Titer kit,
Cells Biolabs) was used according to manufacturer’s protocol to
quantify viral titres.
Figure 5. Binding of mAb 1A9 to wild-type, mutant D1128A, mutant N1056K and mutant D1128A/N1056K S proteins by Western
Blot and immunoprecipitation. 293 FT cells were transfected with no plasmid (mock) or with plasmids expressing full length wild-type S (S-WT)
or full length mutant S (S-D1128A, S-N1056K and S-D1128A/N1056K). (A) Western Blot analysis was performed on the cell lysates using mAb 1A9 to
determine if it can bind to the different S proteins. MAb 7G12, which binds to the S1 of the S protein, was used as a control antibody to detect protein
expression. (B) Cell lysates containing S-WT, S-D1128A, S-N1056K or S-D1128A/N1056K were subjected to immunoprecipitation (IP) using mAb 1A9 or
7G12 and protein A beads. S proteins immunoprecipitated by mAbs 1A9 and 7G12 were detected using rabbit anti-SD1 antibody in Western blot
analysis (WB). The rabbit anti-SD1 antibody binds to amino acids 48–358 of the S1 subunit.
doi:10.1371/journal.pone.0102415.g005
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In vitro S-pp neutralization assay
All S-pp neutralization assays were carried out in 24-well plates.
CHO-ACE2 cells were grown in 500 ul of growing media per well
for 24 hours before each experiment. In S-pp neutralization
assays, 16 ng of S-pp (as quantified using P24 ELISA) were pre-
incubated with mAb 1A9 or mAb 1G10 at 0, 25, 50, 100, 150 and
200 mg/ml for 1 hour at room temperature. The mAb-virus
mixtures or virus alone were used to infect CHO-ACE2 cells and
incubated at 37uC. A non-neutralizing anti-S1 antibody that binds
to the RBD of S, mAb 7G12 [31], was used as a control antibody
at 200 mg/ml. At 48 hours post-infection, cells were harvested
using the luciferase assay system (Promega) and luciferase
expressions of the cells were determined according to manufac-
turer’s protocol. Percentages of viral entry were then calculated
based on the luciferase readings obtained. All experiments were
carried out in triplicates. Statistical difference in viral entry
between wild-type and mutant S-pp was done using unpaired t-
test. Significance was indicated by p-value of ,0.01.
ELISA for quantifying the amount of S protein in S-pp
S-pps were coated onto 96-well ELISA plates (Nunc) at 16 ng/
well (as quantitated P24 ELISA) overnight at 4uC. The wells were
blocked in 5% skimmed milk in PBS with 0.1% Tween 20 (PBST),
and primary antibodies (mAb 7G12 [31] and mouse anti-P24
antibody) were added as primary antibodies at 4-fold dilutions and
incubated at 37uC for 2 hours. The wells were then washed in
PBST followed by the addition of goat anti-mouse HRP-
conjugated antibody (Pierce) as secondary antibody and incubated
at 37uC for 1 hour. Tetramethylbenzidine substrate (Pierce) was
added and reaction was stopped using 0.2 M sulphuric acid.
OD450 nm was obtained using an absorbance reader (Tecan
Infinite M200). Difference in S protein level in wild-type and
mutant D1128A S-pp was evaluated using unpaired t-test.
Fluorescence-activated Cell Sorting (FACS) analysis for
surface expression of S protein
293 FT cells were seeded in 6-cm dishes 24 hours prior to
transfection. The cells were transfected with pXJ39 empty vector,
Figure 6. Neutralization of wild-type, mutant D1128A, N1056K and D1128A/N1056K S-pps by mAb 1A9 and mAb 1G10. S-pp
containing wild-type (S-WT-pp) or mutant S (S-D1128A-pp, S-N1056K-pp and S-D1128A/N1056K-pp) were pre-incubated with different
concentrations of (A) mAb 1A9 or (B) mAb 1G10 at 25, 50, 100 and 200 mg/ml for 1 hour before infecting CHO-ACE2 cells. An anti-S1, non-
neutralizing mAb 7G12 was used as control antibody at 200 mg/ml. Cells were harvested 48 hours post-infection and luciferase activities were
measured. Viral entry, as indicated by the luciferase activity measured in relative light units (RLU), was expressed as a percentage of the reading
obtained in the absence of antibody, which was set at 100%. Data shown represents that obtained from 3 independent experiments. Bars represent
SD of the experiment carried out in triplicates. *indicates statistically significant difference of p,0. 01 when compared to S-WT-pp.
doi:10.1371/journal.pone.0102415.g006
Characterization of SARS Coronavirus Antibody Escape Virus
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e102415
pXJ39-S and pXJ39-S-D1128A plasmids using Lipofectamine
2000 reagent (Invitrogen) according to manufacturer’s protocol
and harvested at 72 hours post-transfection. The cells were first
detached using the cell dissociation solution (Sigma), washed twice
in 1x PBS and incubated with purified mouse mAb 7G12 [31]
(that binds to the S1 subunit) in 1x PBS containing 1% bovine
serum albumin (BSA) for 3 hours at 4uC on a nutator. The cells
were washed 3 times using 1x PBS containing 1% BSA and then
incubated with fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse IgG (Santa Cruz) secondary antibody for 1 hour at
4uC on the nutator. Cells were washed again 3 times and
immediately used for FACS analysis using the CyAn flow
cytometer (Beckman Coulter). All FACS data was analysed using
the FlowJo software application.
Results
In vitro neutralization of civet and bat S-pps by mAb 1A9
As described in our previous publication, we have a panel of
neutralizing mAbs largely grouped into Type I, II, III and IV
based on their binding sites on the S protein. By membrane fusion
experiment, we found that mAb 1A9 belonging to Type II was the
most effective in cell-cell membrane blocking and bound to
residues 1111-1130 which are immediately upstream of the HR2
domain (Figure 1A) [31]. As the contribution of the mAb 1A9
binding site to the structure and function of S has not been
defined, we chose mAb 1A9 for further investigation in this study
in order to gain a better understanding of the neutralizing
mechanism of mAb 1A9.
Sequence alignment shows that residues 1111-1130 is a highly
conserved region within the S2 subunit of human, civet SARS-
CoV and bat SL-CoV strains (Figure 1B). It has been demon-
strated by Ren et al. [7] that the bat SL-CoV Rp3 uses a different
unknown receptor for entry and thus, could not infect cells
expressing human ACE2 receptor. In order to evaluate the viral
entry properties of the civet SARS-CoV SZ3, bat SL-CoV Rp3
and Rf1 strains, the receptor-binding domain (RBD) of S in the
civet SARS-CoV SZ3 strain and bat SL-CoV Rp3 and Rf1 strains
were replaced with the RBD of S in the human SARS-CoV to
create chimeric S proteins (Figure 2A) to allow viral attachment
step through the binding of the RBD of S to human ACE2
receptor. By Western blot analysis, mAb 1A9 was found to be able
to bind to the S2 subunits of the civet SARS-CoV SZ3 and bat SL-
CoV Rp3 and Rf1 strains to similar extent as the homologous
human SARS-CoV HKU39849 (Figure 2B). An antibody
targeting the S1 domain of the human SARS-CoV S protein,
mAb 7G12 [31], was used to determine the relative expressions of
the chimeric S proteins (Figure 2B).
Next, to determine if mAb 1A9 exhibits cross-neutralizing
activity, S-pseudotyped virus particles, or S-pps, carrying the
human SARS-CoV S or the various RBD-modified chimeric S of
civet SARS-CoV SZ3 strain and bat SL-CoV Rp3 and Rf1 strains
Figure 7. Determination of cell surface expression of wild-type and mutant D1128A S proteins by FACS analysis and determination
of wild-type and mutant D1128A S protein incorporation in S-pp by ELISA. (A) FACS analysis was performed with 293 FT cells were
transfected with empty vector (full line) or with plasmids expressing full length wild-type S (dotted line) or full length mutant D1128A S (dash line).
Cells were harvested 72 hours post-transfection and stained with mouse mAb 7G12, followed by FITC-conjugated goat anti-mouse antibody. Results
shown are representative of 3 independent experiments. (B) Pseudoviral particles not expressing S (pNL43-R-E-Luc virus), S-pp expressing wild-type S
(S-WT-pp) and mutant D1128A S (S-D1128A-pp) were coated on a 96-well plate at 16 ng/well, as previously quantitated using P24 ELISA, and
detected using mAb 7G12 (top) and mAb P24 (bottom) at 4-fold serial dilutions. Optical density (OD) was measured at 450 nm. Bars represent SD of
the experiment carried out in triplicates. MAb P24 was used as a control antibody to ensure equal amounts of S-pp were coated onto each well.
doi:10.1371/journal.pone.0102415.g007
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were generated and used to infect CHO-ACE2 cells in the absence
or presence of different concentrations (100, 150 and 200 mg/ml)
of mAb 1A9. In this pseudotyped virus system, replication
incompetent lentiviral particles that express S proteins on the
surface were used in replacement of live SARS-CoVs and SL-
CoVs. This system has been successfully employed in the study of
highly pathogenic viruses including the influenza virus [33] and
SARS-CoV [34,35,36]. Neutralizing antibody titers measured
using pseudotyped SARS-CoV correlated well with the use of
replication competent SARS-CoV [37], as such, this system has
been widely used in the evaluation of SARS-CoV neutralizing
antibodies [30,38,39,40,41]. In this study, the S-pps expressing
human SARS-CoV S or RBD-modified chimeric S of civet SARS-
CoV SZ3 strain and bat SL-CoV Rp3 and Rf1 strains were able to
infect and enter CHO-ACE2 cells at similar extent (Figure S1A in
File S1). The results obtained from the mAb 1A9 neutralization
assay (Figure 2C, Figure S2 in File S1) showed that mAb 1A9,
apart from being able to neutralize S-pp expressing human SARS-
CoV HKU39849 S, was able to cross-neutralize the S-pp
expressing chimeric S of civet SARS-CoV SZ3 and bat SL-CoV
Rp3 and Rf1. This indicates that mAb 1A9 has broad neutralizing
capability.
Generation of mAb 1A9 escape mutants and
identification of S mutations in mAb 1A9 escape mutants
To identify critical residue(s) required for mAb 1A9 interaction
with S, mAb 1A9 escape mutants were generated. SARS-CoV
HKU39849 strain was cultured in Vero E6 cells at a sub-optimal
level of mAb 1A9 (0.25 mg/ml). Supernatant from the wells
containing cells that exhibited cytopathic effect (CPE) at the
highest dilution of SARS-CoV was harvested as passage 1 and
passaged 3 times in the presence of mAb 1A9 (0.25 mg/ml), after
which the virus titres gradually increased (Figure 3) and a plaque
assay was done to isolate 5 individual SARS-CoV escape mutant
clones.
The wild-type and escape mutant viruses were used at 1000
TCID50 and subjected to neutralization assays by mAb 1A9 and
mAb 1G10 in Vero E6 cells to determine cytopathic effects (CPE).
All 5 escape mutant clones were resistant to neutralization by mAb
1A9 and the result of one representative clone is shown in Figure 4.
The percentage of CPE in Vero E6 cells infected with wild-type
virus decreased significantly at mAb 1A9 concentrations .1 mg/
ml (Figure 4A). In contrast, 100% CPE was still observed in escape
mutant virus-infected cells even in the presence of 2 mg/ml of
mAb 1A9 (Figure 4B), indicating that the mutant virus is resistant
to neutralization by mAb 1A9. However, both the wild-type and
mutant virus were equally sensitive to neutralization by another
mAb 1G10 (Figure 4C and D), which binds to an epitope (residues
1151–1192) in S2 different from that of mAb 1A9 [31]. After
confirming the escape ability of the escape mutant clones, the viral
RNA was extracted and the S gene was sequenced. Two escape
mutations, N1056K and D1128A, were identified in the mAb 1A9
escape mutants. 2 out of 5 clones had D1128A mutation and 3 out
of 5 clones had N1056K mutation. None of the clones had both
mutations.
Difference in mAb 1A9 binding to wild-type and mutant
S proteins
Wild-type S, substitution S mutants, namely D1128A, N1056K,
and that containing both D1128A and N1056K, were then
expressed in 293 FT cells and Western Blot analysis was
performed to determine the effects of these mutations on the
binding of the S protein to mAb 1A9. As shown in Figure 5A, S
protein containing mutation D1128A (S-D1128A) showed a
reduced binding to mAb 1A9 compared to the wild-type S protein
(S-WT), while S protein with the N1056K mutation (S-N1056K)
did not show a reduction in mAb 1A9 binding compared to S-WT.
While Western Blot reveals the binding of mAb 1A9 to denatured
epitope on S, immunoprecipitation (IP) was performed to compare
the mAb 1A9 binding to native forms of S. Consistent with the
results obtained in Western Blot analysis, S-D1128A exhibited a
decrease in mAb 1A9 binding compared to S-WT while S-
N1056K did not (Figure 5B). Similar results were also observed in
ELISA (Figure S3 in File S1) using wild-type and mutant D1128A
and N1056K GST-S(1030-1188) fragments that were expressed
from bacteria cells (Figure S4 in File S1). These results suggest that
residue 1128 is important in the binding of mAb 1A9 to the S
protein. In addition, S protein containing both mutations was
evaluated for synergistic effects in the reduction of mAb 1A9
binding by Western Blot and immunoprecipitation. As shown in
Figure 5A and B, no significant synergistic effect was observed.
Resistance of S-pp expressing mutant D1128A S protein
to neutralization by mAb 1A9
Both D1128A and N1056K are mutations identified in escape
SARS-CoV mutant clones generated against mAb 1A9. To verify
if these two mutations contribute to the escape from neutralization
by mAb 1A9 in an in vitro pseudotyped virus assay, S-pps
expressing the wild-type, mutant D1128A, mutant N1056K and
mutant D1128A/N1056K S proteins were generated. As seen in
Figure S1B in File S1, all S-pps were able to infect and enter
CHO-ACE2 cells, with the mutant S-pps showing a slightly lower
infectivity compared to wild-type. They were then used to infect
CHO-ACE2 cells in the absence or presence of different
concentrations (25, 50, 100 and 200 mg/ml) of mAb 1A9 and
the neutralization activities of mAb 1A9 against wild-type S-pp, S-
D1128A-pp, S-N1056K-pp and S-D1128A/N1056K-pp were
compared. MAb 7G12, an anti-S1, non-neutralizing mAb, was
used as the control antibody at 200 mg/ml. As shown in Figure 6A
and Figure S5A in File S1, at the highest concentration of 200 mg/
ml, mAb 1A9 prevented the viral entry of wild-type S-pp and S-
N1056K-pp in CHO-ACE2 cells by 36% and 35% respectively,
while the entry of S-D1128A-pp was not significantly affected. At
lower concentrations of mAb 1A9 (25, 50 and 100 mg/ml), similar
results were obtained, suggesting that S-D1128-pp was resistant to
mAb 1A9 neutralization. This further indicates that through a
reduction in binding to mAb 1A9 (as observed in Western Blot, IP
and ELISA), the D1128A mutation in S protein is sufficient to
mediate the escape from neutralization by mAb 1A9. In addition,
S-pp containing both D1128A and N1056K mutations was
investigated for its resistance to mAb 1A9 neutralization. S-
D1128A/N1056K-pp was also resistant to mAb 1A9 neutraliza-
tion at a similar extent as the S-D1128A-pp (Figure 6A and Figure
S5A in File S1), indicating no synergistic effects between the
D1128A and N1056K mutations in conferring mAb 1A9
resistance to the viral particles. No resistance to neutralization
was observed for all S-pp with mAb 1G10, another neutralizing
mAb that binds to a different epitope within the S2 subunit at
amino acids 1151–1192 (Figure 6B and Figure S5B in File S1).
Effects of D1128A mutation on the expression of S
protein on cell surface and incorporation of S protein
incorporation into S-pp
Mutations within the coronavirus S protein can have profound
effects on the synthesis and maturation process of the S protein,
resulting in decreased cell surface expression as well as defects in its
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incorporation into matured virion particles. To evaluate the
possible effects of D1128A mutation on the maturation process of
the S protein during its synthesis, FACS analysis was performed to
compare the cell surface expression of wild-type (WT) and mutant
D1128A S proteins in transfected 293 FT cells. Vector-transfect-
ed, wild-type S-transfected and mutant D1128A S-transfected cells
were incubated with mAb 7G12 (which binds to the S1 subunit of
S) followed by an FITC-conjugated anti-mouse secondary
antibody. A positive shift in fluorescence was observed in the
wild-type S-expressing cells when compared to the vector-
transfected cells (Figure 7A) because of the specific binding of
mAb 7G12 to the native form of the S protein expressed on the
cell surface. In comparison, the mutant D1128A S-expressing cells
showed similar degree of shift in fluorescence as those expressing
wild-type S (Figure 7A). Thus, the D1128A mutation did not
reduce the surface level expression of the S protein, suggesting that
this substitution at residue 1128 did not hamper the synthesis and
processing of the S protein.
To determine if the mutant D1128A S protein is incorporated
into the S-pps as efficiently as wild-type S, equal amount of wild-
type S-pp and S-D1128A-pp was coated onto an ELISA plate and
mAb 7G12 was used to compare the amount of S protein in the S-
pps. It was observed that there was no significant difference in the
expression of wild-type and mutant D1128A S protein in the S-pps
(Figure 7B, top). This indicates that the mutation did not cause any
change in the efficiency of S protein incorporation into viral
particles. When an anti-HIV-1 P24 mAb was used instead of mAb
7G12, the OD450 nm readings obtained were similar, confirming
that equal amounts of S-pp viruses were successfully coated on the
ELISA plate (Figure 7B, bottom).
Discussion
Although there has been no reported case of SARS-CoV
infection in humans since 2004, the development of anti-SARS-
CoV treatments and vaccines remains crucial as the threat of a re-
emergence of SARS exists till today. Human and civet SARS-
CoVs are believed to have originated from SL-CoVs residing in
bats [42]. As coronaviruses are known to be capable of frequent
cross-species transmission [12], the continual persistence of SL-
CoVs in animal hosts and reservoirs poses a threat to humans
should a cross-species transmission occurs. The development of
broadly neutralizing mAbs that confer cross-protection not only
against human SARS-CoV, but also zoonotic strains of SARS-
CoV and SL-CoV, is therefore important. The putative S1 subunit
of bats SL-CoVs has a low sequence homology of about 63% to
that of SARS-CoV, especially in the RBD, indicating the usage of
different host cell receptors and different tissue tropisms [43]. On
the other hand, the high sequence homology in the S2 subunit of
about 92–96% suggests that the fusion mechanism during viral
infection is well-conserved [44]. Broadly neutralizing mAbs usually
target conserved epitopes required for highly conserved process,
such as the post-attachment fusion process [45]. A majority of
SARS-CoV-neutralizing mAbs reported bind and target the S1
protein at the RBD region [46]. Nonetheless, neutralizing mAbs
that bind to the S2 subunit have been reported. The epitopes of
these mAbs are found to be located at the S2 subunit upstream of
HR1 (residues 787–809, 791–805) [47,48], within the loop region
in between HR1 and HR2 (residues 1023–1189) [31,40] and
within the HR2 domain (residues 1151–1192) [31]. It has also
been shown that anti-S2 mAbs that bind to the highly conserved
HR1, HR2 and ectodomain of the SARS-CoV S protein were
able to neutralize a wider range of clinical isolates, including
human and zoonotic strains of SARS-CoVs [28,30]. In this
current study, mAb 1A9, an anti-S2 mAb that binds to the S2
subunit at the highly conserved loop region at residues 1111–1130,
was demonstrated to be able to cross-neutralize pseudotyped S-pp
viruses of the human SARS-CoV, civet SARS-CoV and bat SL-
CoV strains. This is consistent with the sequence conservation of
the mAb 1A9 binding epitope in S. In addition, sequence
alignment (not shown) revealed that the mAb 1A9 binding site is
also conserved in other bat CoVs such as the Bulgarian SARS-
related CoV strain [49], indicating the potential cross-protective
effect of mAb 1A9 against not only bat SL-CoV from China, but
also from other parts of the world such as Europe.
Several cross-neutralizing mAbs against human and civet
SARS-CoV strains targeting the RBD have been described, with
IC50 values ranging from 0.01 to 0.5 mg/ml [38,39,50,51]. As
observed in this study, the IC50 value of mAb 1A9 is between 25–
50 mg/ml, which is higher than that of RBD-targeting mAbs,
indicating the lower potency of mAb 1A9. Higher IC50 values and
lower potency have also been observed in several other anti-S2
mAbs [40,52]. This can possibly be attributed to the inaccessibility
of the S2 subunit, which constitutes the stalk region of S, as
compared to the S1 subunit that is exposed on the viral surface
[53]. However, SARS-CoV is capable of attaining mutations in
the RBD region without affecting viral infectivity [54], leading to
escape in mAb neutralization, while mutations within the highly
conserved S2 subunit region are more likely to be detrimental to
the mutant virus. Therefore, the characterization of anti-S2 mAbs
remains important in the development of antibodies as anti-viral
therapies against SARS-CoV.
Through the generation of mAb 1A9 escape virus, it was found
that the escape mutation D1128A in the S protein resulted in
diminished binding to mAb 1A9 and S pseudotyped viral particles
containing the D1128A mutation could not be neutralized by mAb
1A9. In addition, the substitution of D1128 by either N (having
same side-chain as D) or E (having same charge as D) also reduced
the interaction with mAb 1A9 to similar extent as the A
substitution (Figure S6 in File S1). Thus, it appears that the D
residue at position 1128 in the S protein plays an essential role in
the interaction with mAb 1A9. Another mutation, N1056K, also
identified in mAb 1A9 escape virus, was found to have no effects
on mAb 1A9 binding and neutralization, indicating that this is
most likely a random mutation that arose during the generation of
escape mutants. No significant synergistic effect was observed
between the D1128A and N1056K mutations in decreasing mAb
1A9 binding and conferring resistance to mAb 1A9 neutralization.
As there is no information on the possible functional role of the
mAb 1A9 binding epitope or the residue D1128, the cell surface
expression of mutant S-D1128A and its incorporation into viral-
like particles was compared to that of wild-type S. The results
showed that S-D1128A is similar to wild-type S in these aspects,
suggesting that viral entry property of the escape virus has not
changed. In summary, we characterized mAb 1A9, a SARS-CoV
neutralizing mAb that binds to a novel epitope located within the
loop region located in between HR1 and HR2, at a position
directly upstream of HR2 at residues 1111–1130 of the S protein
that has not been previously identified and characterized. The
aspartic acid at residue 1128 is crucial for the interaction of S
protein with mAb 1A9 and a substitution to alanine in the escape
virus is sufficient to abolish neutralization by mAb 1A9 but has
little effect on the viral entry property. Consistently, while a
detailed study on the fitness of the escape virus has not been
performed, it was observed that the virus titre of the escape virus
after 3 passages in presence of mAb 1A9 reached similar level as
the wild-type virus (see Figure 3). However, we cannot rule out the
possibility that the mutation may affect viral virulence and further
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work is needed to address this. The loop region in between HR1
and HR2 in the S2 subunit is believed to be a region required for
viral-cell membrane fusion, as peptides analogous to the loop
region were found to inhibit SARS-CoV infection [55]. Although
D1128 residue has not been shown to be directly involved in
membrane fusion, it is probable that the binding of mAb 1A9 to
the D1128 residue in the loop region causes steric hindrance that
prevents the association of HR1 and HR2 to form the six-helical
fusion bundle core. Hence, structural analysis of the interaction
between mAb 1A9 and S is actively being pursued in order to
define the inhibition mechanism of mAb 1A9.
Supporting Information
File S1 Supporting information Figures S1–S6. Figure S1.
Infectivity of pseudotyped viruses expressing S protein (S-pps). (A)
S-pp expressing S protein of humans SARS-CoV HKU39849,
civet SARS-CoV SZ3, bat SL-CoV Rp3 and Rf1 and (B) S-pp
containing wild-type or mutant D1128A, N1056K or D1128A/
N1056K S were generated and used to infect CHO-ACE2 cells at
equal amount (as quantitated using P24 ELISA). Cells were
harvested 48 hours post-infection and luciferase readings were
measured. pNL43-R-E-Luc virus, which do not express S protein,
was used as negative control. Error bars represent SD of
experiment carried out in triplicates. Figure S2. Neutralization
of human SARS-CoV HKU39849, civet SARS-CoV SZ3, bat SL-
CoV Rp3 and Rf1 S-pps by mAb 1A9 (data presented using
absolute luciferase readings). S-pps containing S of human SARS-
CoV HKU39849, civet SARS-CoV SZ3, bat SL-CoV Rp3 or
Rf1, were pre-incubated with different concentrations of mAb 1A9
at 100, 150 and 200 mg/ml for 1 hour before infecting CHO-
ACE2 cells. Cells were harvested 48 hours post-infection and
luciferase activities were measured. Data shown represents that
obtained from 3 independent experiments. Bars represent SD of
the experiment carried out in triplicates. Figure S3. Binding of
mAb 1A9 to wild-type, mutant D1128A and N1056K GST-
S(1030-1188) fragments by ELISA. In ELISA, GST, GST-S(1030-
1188) wild-type, GST-S(1030-1188)-D1128A and GST-S(1030-
1188)-N1056K proteins were coated on a 96-well plate at 100 ng/
well and detected using (C) mAb 1A9 and (D) mAb GST at 4-fold
serial dilutions. Optical density (OD) was measured at 450 nm.
Bars represent SD of the experiment carried out in triplicates.
*indicates statistically significant difference (p,0.01) when com-
pared to wild-type. MAb GST was used as a control antibody to
ensure that equal amounts of GST-tagged proteins were coated
onto each well. A significant reduction of mAb 1A9 binding was
observed for S fragment containing the D1128A mutation (p,
0.01). Figure S4. Expression and purification of wild-type and
mutant GST-S(1030-1188) fragments. Purified GST, GST-
S(1030-1188) wild-type, GST-S(1030-1188)-D1128A and GST-
S(1030-1188)-N1056K fragments (lanes 1–4) were separated on a
12% gel by SDS-PAGE and stained using Commassie Blue.
Molecular weight markers in kDa are indicated on the left.
Expected size of each GST-S(1030-1188) fragment is around
43 kDa as indicated by the arrow. Figure S5. Neutralization of
wild-type and mutant D1128A, N1056K and D1128A/N1056K
S-pps by mAb 1A9 and mAb 1G10 (data presented using absolute
luciferase readings). S-pp containing wild-type (S-WT-pp) or
mutant S (S-D1128A-pp, S-N1056K-pp and S-D1128A/
N1056K-pp) were pre-incubated with different concentrations of
(A) mAb 1A9 and (B) mAb 1G10 at 25, 50, 100 and 200 mg/ml for
1 hour before infecting CHO-ACE2 cells. An anti-S1, non-
neutralizing mAb 7G12 was used as control antibody at 200 mg/
ml. Cells were harvested 48 hours post-infection and luciferase
activities were measured. Data shown represents that obtained
from 3 independent experiments. Bars represent SD of the
experiment carried out in triplicates. *indicates statistically
significant difference of p,0. 01 when compared to S-WT-pp.
Figure S6. Binding of mAb 1A9 to wild-type, mutant D1128A,
D1128E, D1128N and N1056K S proteins. 293 FT cells were
transfected with no plasmid (mock) or with plasmids expressing full
length wild-type S (S-WT) or full length mutant S (S-D1128A, S-
D1128E, S-D1128N and S-N1056K). Western Blot analysis was
performed on the cell lysates using mAb 1A9 to determine its
binding to the various S proteins. MAb 7G12, which binds to the
S1 of the S protein, was used as a control antibody to detect
protein expression.
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